Delivery Order SPE2DB22D3009-SPE2DB25FBF35
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,240.57 to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 40 mg, a Schedule II controlled substance commonly prescribed for attention-deficit/hyperactivity disorder. The contract was competitively awarded on June 25, 2025, with an ultimate completion date of June 26, 2025, and is classified as a firm fixed-price delivery order with no set-aside designation. Performance will occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,051.06 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 30 mg, a Schedule II controlled substance commonly used to treat attention deficit hyperactivity disorder. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a $2,949.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 40 mg, a controlled substance commonly prescribed for attention deficit hyperactivity disorder. This delivery order, issued on September 8, 2025, with completion targeted for September 9, 2025, represents a routine pharmaceutical procurement to support federal medical supply needs. The contract was competitively awarded with no set-aside designation...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,367.34 for 100 capsules of Lisdexamfetamine 50 mg, a Schedule II controlled substance commonly prescribed for attention-deficit/hyperactivity disorder. Issued on August 27, 2025, with an ultimate completion date of August 28, 2025, this firm fixed price delivery order represents a competitive award with no set-aside designation. The pharmaceutical product will be performed and delivered from...
- The Defense Logistics Agency awarded a $2,010.28 delivery order to AmerisourceBergen Drug Corp for 90 capsules of Lisdexamfetamine 60 mg, a controlled pharmaceutical product used to treat attention-deficit/hyperactivity disorder. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery...
- The Defense Logistics Agency awarded a $2,181.08 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 30 mg, a controlled pharmaceutical used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, which became effective on August 5, 2025 with an ultimate completion date of August 6, 2025, was awarded without a set-aside designation through open competition. The order will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,768.95 for 90 capsules of Lisdexamfetamine 60 mg on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $4,018.27 delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 70 mg capsules (90-count supply) under a firm fixed-price contract. This delivery order, awarded on July 18, 2025, with completion targeted for July 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively made with no set-aside designation, and performance will be fulfilled...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 40 mg capsules (100 count) valued at $10,977.83. The contract, awarded on September 4, 2025, with an ultimate completion date of September 5, 2025, utilizes firm fixed pricing with no set-aside designation. Performance will be conducted from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $10,066.22 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units). This is a firm fixed-price delivery order with an ultimate completion date of September 19, 2025, and represents a non-competitive set-aside contract. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBF35Delivery Order
The Defense Logistics Agency awarded a $2,425.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 70 mg, a Schedule II controlled substance commonly prescribed for attention-deficit/hyperactivity disorder treatment. The order was awarded on September 18, 2025, with an ultimate completion date of September 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This is a non-set-aside competitive award issued under AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. This delivery order represents a routine pharmaceutical procurement supporting federal medical supply chain operations. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for military and veteran healthcare systems through its $999,999,999.00 indefinite delivery contract with DLA Troop Support Medical (designated SPE2DX) running through December 2026. This comprehensive global pharmaceutical support vehicle enables the company to supply a broad range of brand-name and generic medications, vaccines, and medical supplies to support Defense Health Agency operations and other government healthcare systems worldwide. The contractor's contract award history demonstrates consistent capability in meeting federal procurement requirements through open competition across diverse pharmaceutical therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 9/18/25 |